, Volume 48, Issue 6, pp 428–433 | Cite as

Regional brain metabolite abnormalities in inherited prion disease and asymptomatic gene carriers demonstrated in vivo by quantitative proton magnetic resonance spectroscopy

  • A. D. WaldmanEmail author
  • R. J. Cordery
  • D. G. MacManus
  • A. Godbolt
  • J. Collinge
  • M. N. Rossor
Functional Neuroradiology



Inherited prion diseases are caused by mutations in the gene which codes for prion protein (PrP), leading to proliferation of abnormal PrP isomers in the brain and neurodegeneration; they include Gerstmann–Sträussler–Scheinker disease (GSS), fatal familial insomnia (FFI) and familial Creutzfeldt–Jakob disease (fCJD).


We studied two patients with symptomatic inherited prion disease (P102L) and two pre-symptomatic P102L gene carriers using quantitative magnetic resonance spectroscopy (MRS). Short echo time spectra were acquired from the thalamus, caudate region and frontal white matter, metabolite levels and ratios were measured and z-scores calculated for individual patients relative to age-matched normal controls. MRS data were compared with structural magnetic resonance imaging.


One fCJD case had generalised atrophy and showed increased levels of myo-inositol (MI) in the thalamus (z=3.7). The other had decreased levels of N-acetylaspartate (z=4) and diffuse signal abnormality in the frontal white matter. Both asymptomatic gene carriers had normal imaging, but increased frontal white matter MI (z=4.3, 4.1), and one also had increased MI in the caudate (z=5.3).


Isolated MI abnormalities in asymptomatic gene carriers are a novel finding and may reflect early glial proliferation, prior to significant neuronal damage. MRS provides potential non-invasive surrogate markers of early disease and progression in inherited prion disease.


Prion CJD Spectroscopy MRI 



The authors would like to acknowledge the financial support of the Medical Research Council (grant G9627315), the assistance of colleagues in the Dementia Research Group, MRC Prion Unit and National Prion Clinic, and statistical advice from Hilary Watt, from the Institute of Neurology.

Conflict of interest statement We declare that we have no conflict of interest.


  1. 1.
    Collinge J, Brown J, Hardy J, Mullan M, Rossor MN, Baker H, et al (1992) Inherited prion disease with 144 base pair gene insertion: II: clinical and pathological features. Brain 115:687–710PubMedCrossRefGoogle Scholar
  2. 2.
    Collinge J, Palmer MS, Dryden AJ (1991) Genetic predisposition to iatrogenic Creutzfeldt-Jakob disease. Lancet 337:1441–1442CrossRefPubMedGoogle Scholar
  3. 3.
    Palmer MS, Dryden AJ, Hughes JT, Collinge J (1991) Homozygous prion protein genotype predisposes to sporadic Creutzfeldt-Jakob disease. Nature 352:340–342CrossRefGoogle Scholar
  4. 4.
    Collinge J (2001) Prion diseases of humans and animals: their causes and molecular basis. Annu Rev Neurosci 24:519–550CrossRefPubMedGoogle Scholar
  5. 5.
    Zeidler M, Sellar RJ, Collie DA, et al (2000) The pulvinar sign on magnetic resonance imaging in variant Creutzfeldt-Jakob disease. Lancet 355:1412–1418CrossRefPubMedGoogle Scholar
  6. 6.
    Collie DA, Sellar RJ, Zeidler M, Colchester ACF, Knight R, Will RG (2001) MRI of Creutzfeldt-Jakob disease: imaging features and recommended MRI protocol. Clin Radiol 56:726–739CrossRefPubMedGoogle Scholar
  7. 7.
    Imaiso Y, Mitsuo K (1998) Gerstmann-Straussler-Scheinker syndrome with a Pro102Leu mutation in the prion protein gene and atypical MRI findings, hyperthermia, tachycardia, and hyperhidrosis. Rinsho Shinkeigaku 38:920–925PubMedGoogle Scholar
  8. 8.
    Nitrini R, Mendonca RA, Huang N, LeBlanc A, Livramento JA, Marie SK (2001) Diffusion-weighted MRI in two cases of familial Creutzfeldt-Jakob disease. J Neurol Sci 184:163–167CrossRefPubMedGoogle Scholar
  9. 9.
    Fox NC, Freeborough PA, Mekkaoui KF, Stevens JM, Rossor MN (1997) Cerebral and cerebellar atrophy on serial magnetic resonance imaging in an initially symptom free subject at risk of familial prion disease. BMJ 4(315):856–857Google Scholar
  10. 10.
    Bruhn H, Weber T, Thorwirth V, Frahm J (1991) In-vivo monitoring of neuronal loss in Creutzfeldt-Jakob disease by proton magnetic resonance spectroscopy. Lancet 337:1610–1611CrossRefPubMedGoogle Scholar
  11. 11.
    Graham GD, Petroff OAC, Blamire AM, Rajkowska G, Goldman-Rakic P, Prichard JW (1993) Proton magnetic resonance spectroscopy in Creutzfeldt-Jakob disease. Neurology 43:2065–2068PubMedGoogle Scholar
  12. 12.
    Pandya HG, Coley SC, Wilkinson ID, Griffiths PD (2003) Magnetic resonance spectroscopy abnormalities in sporadic and variant Creutzfeldt-Jakob disease. Clin Radiol 58:148–153CrossRefPubMedGoogle Scholar
  13. 13.
    Galanaud D, Dormont D, Grabli D, Charles P, Hauw JJ, Lubetzki C, Brandel JP, Marsault C, Cozzone PJ (2002) MR spectroscopic pulvinar sign in a case of variant Creutzfeldt-Jakob disease. J Neuroradiol 29:285–287PubMedGoogle Scholar
  14. 14.
    Cordery R, MacManus D, Rossor MN, Collinge J, Waldman AD (2003) Short TE proton spectroscopy in variant and familial Creutzfeldt-Jakob disease. Proc ISMRM,11th Scientific Meeting, p 102Google Scholar
  15. 15.
    Shyu W-C, Lee C-C, Hsu Y-D, et al (1996) Panencephalitic Creutzfeldt-Jakob disease. Unusual presentation of magnetic resonance spectroscopy. J Neurol Sci 138:157–160CrossRefPubMedGoogle Scholar
  16. 16.
    Konaka K, Kaido M, Okuda Y, et al (2000) Proton magnetic resonance spectroscopy of a patient with Gerstmann-Straussler-Scheinker disease. Neuroradiology 42:662–665CrossRefPubMedGoogle Scholar
  17. 17.
    Provencher SW (1993) Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med 30:672–679PubMedCrossRefGoogle Scholar
  18. 18.
    Behar KL, Boucher R, Fritch W, Manuelidis L (1998) Changes in N-acetylaspartate and myo-inositol detected in the cerebral cortex of hamsters with Creutzfeldt-Jakob disease. Magn Reson Imaging 16:963–968CrossRefPubMedGoogle Scholar
  19. 19.
    Cheng LL, Newell K, Mallory AE, Hyman BT (2002) Gonzalez RG quantification of neurons in Alzheimer and control brains with ex vivo high resolution magic angle spinning proton magnetic resonance spectroscopy and stereology. Magn Reson Imaging 20:527–533CrossRefPubMedGoogle Scholar
  20. 20.
    Brand A, Richter-Landsberg C, Leibfritz D (1993) Multinuclear NMR studies on the energy metabolism of glial and neuronal cells. Dev Neurosci 15:289–298PubMedCrossRefGoogle Scholar
  21. 21.
    Strange K, Emma F, Paredes A, Morrison R (1994) Osmoregulatory changes in myo-inositol content and Na+/myo-inositol cotransport in rat cortical astrocytes. Glia 12:35–43CrossRefPubMedGoogle Scholar
  22. 22.
    Valenzuela MJ, Sachdev P (2001) Magnetic resonance spectroscopy in. Neurology 56:592–598PubMedGoogle Scholar
  23. 23.
    Ironside JW, Bell JE (1997) Florid plaques and new variant Creutzfeldt-Jakob disease. Lancet 350:1475CrossRefPubMedGoogle Scholar
  24. 24.
    Huang W, Alexander GE, Daly EM, Shetty HU, Krasuski JS, Rapoport SI, Schapiro MB (1996) High brain myo-inositol levels in the predementia phase of Alzheimer’s disease in adults with Down’s syndrome. Am J Psychiatry 156:1879–1886Google Scholar
  25. 25.
    Kantarci K, Jack CR, Xu YC, Campeau NG, O’Brien PC, Smith, GE, Ivnik RJ, Boeve, BF, Kokmen E, Tangalos EG, Petersen RC (2000) Regional metabolic patterns in mild cognitive impairment and Alzheimer’s disease. Neurology 55:210–217PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  • A. D. Waldman
    • 1
    • 2
    Email author
  • R. J. Cordery
    • 1
    • 2
  • D. G. MacManus
    • 3
  • A. Godbolt
    • 1
    • 2
  • J. Collinge
    • 4
  • M. N. Rossor
    • 1
    • 2
  1. 1.Dementia Research Group, Department of Neurodegenerative Disease, Institute of NeurologyUniversity College LondonLondonUK
  2. 2.Division of Neuroscience & Psychological Medicine, Faculty of MedicineImperial College of Science, Technology & MedicineLondonUK
  3. 3.NMR Research Unit, Department of Clinical Neurology, Institute of NeurologyUniversity College LondonLondonUK
  4. 4.MRC Prion Unit, Department of Neurodegenerative Disease, Institute of NeurologyUniversity College LondonLondonUK

Personalised recommendations